Author details

Full Name

Eugene Braunwald

Affiliation

ORCID

Career Start Year

1953

Papers

1570

H Index

218

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37933184	Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.	Eur J Heart Fail	2024
36987929	Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation.	Eur J Heart Fail	2023
36303404	Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.	Eur Heart J	2023
36149667	Inhibitors of factor XI: game changers of anti-thrombotic therapy?	European Heart Journal	2023
35980763	A polygenic risk score predicts atrial fibrillation in cardiovascular disease.	Eur Heart J	2023
37804245	Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.		2023
37889202	Inhibition of angiotensinogen in the treatment of hypertension.		2023
37563238	Will primordial prevention change cardiology?		2023
37556796	Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.	Diabetes Care	2023
37611068	Diabetocardiology: a new subspecialty?		2023
37345760	Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT.	J Am Heart Assoc	2023
37344040	Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus.	J Am Coll Cardiol	2023
37212758	Angiotensin-Neprilysin Inhibition inÂ Patients With Mildly Reduced orÂ Preserved Ejection Fraction andÂ Worsening HeartÂ Failure.	J Am Coll Cardiol	2023
37211048	Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trial.	Int J Cardiol	2023
37210743	Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.	Eur Heart J	2023
36796671	Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.	J Card Fail	2023
36617273	Air pollution: challenges and opportunities for cardiology.		2023
37051728	Mitochondrial cardiomyopathy: a fertile field for research.		2023
37100536	Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes.		2023
35139283	Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. Reply.	New England Journal of Medicine	2022
35772853	Tolerability of Sacubitril/Valsartan in Patients With Advanced HeartÂ Failure: Analysis of the LIFE Trial Run-In.	JACC Heart Fail	2022
35969651	Glucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: 50 Years On and Time for a Relook.	Circulation	2022
36367709	Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54.	Eur Heart J	2022
35958690	Cardiac Xenotransplantation: Another Historic First?	JACC: Basic to Translational Science	2022
35507336	Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial?-Reply.	JAMA Cardiol	2022
36017608	Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial.	Europace	2022
36004548	Short interfering RNA: a rapidly developing drug class.	European Heart Journal	2022
35613023	Gliflozins in the Management of Cardiovascular Disease.	New England Journal of Medicine	2022
35417529	Cardiac cell therapy: a call for action.	European Heart Journal	2022
35361474	Sixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present.	American Journal of Cardiology	2022
35789383	Control of residual dyslipidaemic risk.	European Heart Journal	2022
36260325	Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT.	JAMA Cardiol	2022
35661876	Cardiac xenotransplantation: a new path for the treatment of advanced heart failure?	European Heart Journal	2022
33624052	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome.	Eur J Prev Cardiol	2022
34355758	How to live to 100 before developing clinical coronary artery disease: a suggestion.	European Heart Journal	2022
34990581	Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups.	American Heart Journal	2022
34741610	SGLT2 inhibitors: the statins of the 21st century.	European Heart Journal	2022
34730769	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.	JAMA Cardiol	2022
35232819	Changing the Trajectory of Heart Failure and Kidney Disease: A Call for Action.	Clinical journal of the American Society of Nephrology : CJASN	2022
34962979	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.	European Heart Journal - Cardiovascular Pharmacotherapy	2022
34773460	Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.	JAMA Cardiol	2022
35165710	Heart failure: a 70 year Odyssey.	European Heart Journal	2022
35112882	Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT.	J Am Heart Assoc	2022
35086664	Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol.	J Am Coll Cardiol	2022
34365799	Transmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV.	J Am Heart Assoc	2021
33704416	The Birth of Cardiology: The Golden Decade.	European Heart Journal	2021
33587659	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.	Circulation	2021
33587654	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials.	Circulation	2021
34167651	Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?	Journal of the American College of Cardiology	2021
33530704	Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.	Circ Heart Fail	2021